Evidence map›Paper›PMID 25974247›Full record

ArticlePloS one2015

Identification of Disease-Promoting HLA Class I and Protective Class II Modifiers in Japanese Patients with Familial Mediterranean Fever.

Michio Yasunami, Hitomi Nakamura, Kazunaga Agematsu, Akinori Nakamura, Masahide Yazaki, Dai Kishida, Akihiro Yachie, Tomoko Toma, Junya Masumoto, Hiroaki Ida and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Michio YasunamiDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Hitomi NakamuraDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Kazunaga AgematsuDepartment of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Japan.
Akinori NakamuraDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Masahide YazakiDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Dai KishidaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Akihiro YachieDepartment of Pediatrics, Kanazawa University, Kanazawa, Japan.
Tomoko TomaDepartment of Pediatrics, Kanazawa University, Kanazawa, Japan.
Junya MasumotoDepartment of Pathogenomics, Ehime University Graduate School of Medicine, To-on, Japan.
Hiroaki IdaDepartment of Rheumatology, Kurume University School of Medicine, Kurume, Japan.
Tomohiro KogaFirst Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan.
Atsushi KawakamiFirst Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan.
Katsumi EguchiDepartment of Rheumatology, Sasebo City General Hospital, Sasebo, Japan.
Hiroshi FurukawaDepartment of Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan.
Tadashi NakamuraDepartment of Rheumatology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
Minoru NakamuraClinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Kiyoshi MigitaClinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Nagasaki University · JPShinshu University · JPKanazawa University · JPNagasaki Medical Center · JPEhime University · JPKurume University · JPNational Sagamihara Hospital · JPSasebo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe genotype-phenotype correlation of MEFV remains unclear for the familial Mediterranean fever (FMF) patients, especially without canonical MEFV mutations in exon 10. The risk of FMF appeared to be under the influence of other factors in this case. The contribution of HLA polymorphisms to the risk of FMF was examined as strong candidates of modifier genes.

methodsGenotypes of HLA-B and -DRB1 loci were determined for 258 mutually unrelated Japanese FMF patients, who satisfied modified Tel-Hashomer criteria, and 299 healthy controls. The effects of carrier status were evaluated for the risk of FMF by odds ratio (OR). The HLA effects were also assessed for clinical forms of FMF, subsets of FMF with certain MEFV genotypes and responsiveness to colchicine treatment.

resultsThe carriers of B*39:01 were increased in the patients (OR = 3.25, p = 0.0012), whereas those of DRB1*15:02 were decreased (OR = 0.45, p = 0.00050), satisfying Bonferroni's correction for multiple statistical tests (n = 28, p<0.00179). The protective effect of DRB1*15:02 was completely disappeared in the co-existence of B*40:01. The HLA effects were generally augmented in the patients without a canonical MEFV variant allele M694I, in accordance with the notion that the lower penetrance of the mutations is owing to the larger contribution of modifier genes in the pathogenesis, with a few exceptions. Further, 42.9% of 14 colchicine-resistant patients and 13.5% of 156 colchicine-responders possessed B*35:01 allele, giving OR of 4.82 (p = 0.0041).

conclusionsThe differential effects of HLA class I and class II polymorphisms were identified for Japanese FMF even in those with high-penetrance MEFV mutations.

Indexed as

Polymorphism, GeneticAdolescentAdultAsian PeopleChildCytoskeletal ProteinsFamilial Mediterranean FeverFemaleGenes, MHC Class IGenotypeHLA-B AntigensHLA-DRB1 ChainsHumansJapanMaleMiddle AgedCytoskeletal ProteinsHLA-B AntigensHLA-DRB1 ChainsMEFV protein, humanPyrin

Identifiers

PMID25974247
PMCPMC4431852
OpenAlexW314964558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.